Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Trials ; 20(1): 461, 2019 Jul 27.
Artigo em Inglês | MEDLINE | ID: mdl-31351492

RESUMO

BACKGROUND: Periodontal intrabony defects are usually treated surgically with the aim of increasing attachment and bone levels and reducing risk of progression. However, recent studies have suggested that a minimally invasive non-surgical therapy (MINST) leads to considerable clinical and radiographic defect depth reductions in intrabony defects. The aim of this study is to compare the efficacy of a modified MINST approach with a surgical approach (modified minimally invasive surgical therapy, M-MIST) for the treatment of intrabony defects. METHODS: This is a parallel-group, single-centre, examiner-blind non-inferiority randomised controlled trial with a sample size of 66 patients. Inclusion criteria are age 25-70, diagnosis of periodontitis stage III or IV (grades A to C), presence of ≥ 1 'intrabony defect' with probing pocket depth (PPD) > 5 mm and intrabony defect depth ≥ 3 mm. Smokers and patients who received previous periodontal treatment to the study site within the last 12 months will be excluded. Patients will be randomly assigned to either the modified MINST or the M-MIST protocol and will be assessed up to 15 months following initial therapy. The primary outcome of the study is radiographic intrabony defect depth change at 15 months follow-up. Secondary outcomes are PPD and clinical attachment level change, inflammatory markers and growth factors in gingival crevicular fluid, bacterial detection, gingival inflammation and healing (as measured by geometric thermal camera imaging in a subset of 10 test and 10 control patients) and patient-reported outcomes. DISCUSSION: This study will produce evidence about the clinical efficacy and potential applicability of a modified MINST protocol for the treatment of periodontal intrabony defects, as a less invasive alternative to the use of surgical procedures. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03797807. Registered on 9 January 2019.


Assuntos
Perda do Osso Alveolar/terapia , Raspagem Dentária , Regeneração Tecidual Guiada Periodontal , Desbridamento Periodontal , Periodontite/complicações , Aplainamento Radicular , Retalhos Cirúrgicos , Adulto , Idoso , Perda do Osso Alveolar/diagnóstico por imagem , Perda do Osso Alveolar/etiologia , Raspagem Dentária/efeitos adversos , Estudos de Equivalência como Asunto , Feminino , Regeneração Tecidual Guiada Periodontal/efeitos adversos , Humanos , Londres , Masculino , Pessoa de Meia-Idade , Procedimentos Cirúrgicos Minimamente Invasivos , Desbridamento Periodontal/efeitos adversos , Periodontite/diagnóstico , Aplainamento Radicular/efeitos adversos , Índice de Gravidade de Doença , Fatores de Tempo , Resultado do Tratamento , Adulto Jovem
3.
PLoS One ; 12(9): e0183926, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28910330

RESUMO

BACKGROUND: Patients with advanced chronic kidney disease (CKD) experience complex functional and structural changes of the cardiopulmonary and musculoskeletal system. This results in reduced exercise tolerance, quality of life and ultimately premature death. We investigated the relationship between subjective measures of health related quality of life and objective, standardised functional measures for cardiovascular and pulmonary health. METHODS: Between April 2010 and January 2013, 143 CKD stage-5 or CKD5d patients (age 46.0±1.1y, 62.2% male), were recruited prospectively. A control group of 83 healthy individuals treated for essential hypertension (HTN; age 53.2±0.9y, 48.22% male) were recruited at random. All patients completed the SF-36 health survey questionnaire, echocardiography, vascular tonometry and cardiopulmonary exercise testing. RESULTS: Patients with CKD had significantly lower SF-36 scores than the HTN group; for physical component score (PCS; 45.0 vs 53.9, p<0.001) and mental component score (MCS; 46.9 vs. 54.9, p<0.001). CKD subjects had significantly poorer exercise tolerance and cardiorespiratory performance compared with HTN (maximal oxygen uptake; VO2peak 19.9 vs 25.0ml/kg/min, p<0.001). VO2peak was a significant independent predictor of PCS in both groups (CKD: b = 0.35, p = 0.02 vs HTN: b = 0.27, p = 0.001). No associations were noted between PCS scores and echocardiographic characteristics, vascular elasticity and cardiac biomarkers in either group. No associations were noted between MCS and any variable. The interaction effect of study group with VO2peak on PCS was not significant (ΔB = 0.08; 95%CI -0.28-0.45, p = 0.7). However, overall for a given VO2peak, the measured PCS was much lower for patients with CKD than for HTN cohort, a likely consequence of systemic uremia effects. CONCLUSION: In CKD and HTN, objective physical performance has a significant effect on quality of life; particularly self-reported physical health and functioning. Therefore, these quality of life measures are indeed a good reflection of physical health correlating highly with objective physical performance measures.


Assuntos
Hipertensão/fisiopatologia , Falência Renal Crônica/fisiopatologia , Qualidade de Vida , Inquéritos e Questionários , Adulto , Eletrocardiografia , Hipertensão Essencial , Teste de Esforço , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
4.
Trials ; 16: 535, 2015 Nov 25.
Artigo em Inglês | MEDLINE | ID: mdl-26607762

RESUMO

BACKGROUND: Recruitment to trials evaluating the effectiveness of childhood obesity management interventions is challenging. We report our experience of recruitment to the Families for Health study, a randomised controlled trial evaluating the effectiveness of a family-based community programme for children aged 6-11 years, versus usual care. We evaluated the effectiveness of active recruitment (contacting eligible families directly) versus passive recruitment (informing the community through flyers, public events, media). METHODS: Initial approaches included passive recruitment via the media (newspapers and radio) and two active recruitment methods: National Child Measurement Programme (letters to families with overweight children) and referrals from health-care professionals. With slow initial recruitment, further strategies were employed, including active (e.g. targeted letters from general practices) and passive (e.g. flyers, posters and public events) methods. At first enquiry from a potential participant, families were asked where they heard about the study. Further quantitative (questionnaire) and qualitative data (one-to-one interviews with parents/carers), were collected from recruited families at baseline and 3-month follow-up and included questions about recruitment. RESULTS: In total, 194 families enquired about Families for Health, and 115 (59.3 %) were recruited and randomised. Active recruitment yielded 85 enquiries, with 43 families recruited (50.6 %); passive recruitment yielded 99 enquiries with 72 families recruited (72.7 %). Information seen at schools or GP surgeries accounted for over a quarter of enquiries (28.4 %) and over a third (37.4 %) of final recruitment. Eight out of ten families who enquired this way were recruited. Media-led enquiries were low (5 %), but all were recruited. Children of families recruited actively were more likely to be Asian or mixed race. Despite extensive recruitment methods, the trial did not recruit as planned, and was awarded a no-cost extension to complete the 12-month follow-up. CONCLUSIONS: The higher number of participants recruited through passive methods may be due to the large number of potential participants these methods reached and because participants may see the information more than once. Recruiting to a child obesity treatment study is complex and it is advisable to use multiple recruitment strategies, some aiming at blanket coverage and some targeted at families with children who are overweight. TRIAL REGISTRATION: Current Controlled Trials ISRCTN45032201 (Date: 18 August 2011).


Assuntos
Publicidade/métodos , Serviços de Saúde Comunitária , Família , Seleção de Pacientes , Obesidade Infantil/terapia , Sujeitos da Pesquisa , Criança , Correspondência como Assunto , Inglaterra , Família/psicologia , Feminino , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Masculino , Meios de Comunicação de Massa , Aceitação pelo Paciente de Cuidados de Saúde , Obesidade Infantil/diagnóstico , Obesidade Infantil/psicologia , Pesquisa Qualitativa , Encaminhamento e Consulta , Sujeitos da Pesquisa/psicologia , Tamanho da Amostra , Inquéritos e Questionários , Fatores de Tempo
5.
Scand J Haematol ; 32(1): 46-8, 1984 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-6695150

RESUMO

Fibrin(ogen) degradation products (FDP) are assayed adequately in defibrinated citrated plasma provided that fibrin(ogeno)lysis is prevented during coagulation. The practical consequence is that all screening tests for haemostatic function may be carried out in specimens obtained from citrated blood.


Assuntos
Testes de Coagulação Sanguínea/métodos , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Fibrina/metabolismo , Citratos , Fibrinogênio/metabolismo , Fibrinólise , Humanos , Concentração de Íons de Hidrogênio
6.
Scand J Haematol ; 25(1): 19-24, 1980 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-7444371

RESUMO

129 patients with thrombosis were treated with heparin for 5 d and followed with platelet counts and coagulation examinations. Of 77 patients treated with 2 different brands of hog mucosa heparin, only 1 developed persistent thrombocytopenia below 100 X 10(9)/1. Of 52 patients treated with beef lung heparin, 1 patient developed thrombocytopenia. No patient developed intravascular coagulation or activated fibrinolysis during heparin treatment.


Assuntos
Heparina/efeitos adversos , Trombocitopenia/induzido quimicamente , Idoso , Animais , Testes de Coagulação Sanguínea , Bovinos , Feminino , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Heparina/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Especificidade de Órgãos , Contagem de Plaquetas , Embolia Pulmonar/tratamento farmacológico , Especificidade da Espécie , Suínos , Tromboflebite/tratamento farmacológico , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA